Dr. Karmali on the Future of CAR T-Cell Therapy in DLBCL

Reem Karmali, MD
Published: Monday, Oct 23, 2017



Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

As cellular immunotherapy takes the forefront, CAR T-cell therapy is an encouraging modality of therapy, says Karmali. However, there are going to be challenges, such as toxicity management and how to incorporate CAR T-cell therapy into existing modalities of therapy.

Thus far, Karmali is optimistic about the CAR T-cell therapy results and believes it will drastically impact DLBCL.
SELECTED
LANGUAGE


Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

As cellular immunotherapy takes the forefront, CAR T-cell therapy is an encouraging modality of therapy, says Karmali. However, there are going to be challenges, such as toxicity management and how to incorporate CAR T-cell therapy into existing modalities of therapy.

Thus far, Karmali is optimistic about the CAR T-cell therapy results and believes it will drastically impact DLBCL.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x